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Summary Two policies of palliative thoracic radiotherapy for NSCLC have been compared in a randomised
multicentre controlled trial aimed at simplifying the palliative treatment of patients with poor performance
status. A total of 235 patients were entered. They had inoperable, microscopically confirmed disease, too
advanced for 'curative' radiotherapy. Their main symptoms were related to the primary intrathoracic tumour
even if metastases were present, and they had a poor performance status. Patients were allocated at random to
regimens of either 17 Gy given in two fractions of 8.5 Gy 1 week apart (F2 regimen, 117 patients), or a single
fraction of 10 Gy (Fl regimen, 118 patients). Two patients (one in each group) were excluded from all analyses
because they were found to have had previously treated malignant disease and had been admitted in error. On
admission, 95% of the 233 eligible patients had cough, 47% haemoptysis, 59% chest pain, 64% anorexia, and
16% dysphagia. As assessed by the clinicians, these symptoms were palliated in high proportions of patients,
ranging in the F2 group from 48% for cough to 75% for haemoptysis, and in the Fl group from 55% for
anorexia to 72% for haemoptysis and chest pain. For all five symptoms the median duration of palliation was
50% or more of survival. All these results were similar in the two treatment groups. In contrast, on daily
assessment by the patients using a diary card, those treated with the F2 regimen experienced substantially
more dysphagia, which was recorded in 56% of the patients compared with 23% in the Fl group (difference
33%: 95% confidence interval 17-48%). The median survival from randomisation was 100 days in the F2
group and 122 days in the Fl group. The Fl regimen, as it requires only a single attendance for treatment, is
recommended as a palliative regimen for patients with inoperable NSCLC and a poor performance status.
The majority of patients with inoperable NSCLC have
tumour already too advanced for radical radiotherapy at the
time they present, but require palliative treatment for major
symptoms related to intrathoracic tumour (Carrol et al.,
1986). It is usual to treat such patients, either at first presen-
tation or when significant symptoms develop, with a course
of palliative radiotherapy (Mulshine et al., 1986).
An earlier randomised clinical trial (MRC Lung Cancer
Working Party, 1991) showed that in the management of
patients with previously untreated, inoperable NSCLC too
advanced for 'curative' or long-term palliative radiotherapy,
effective palliation ofchest symptoms was achieved with only
two fractions of 8.5 Gy given 1 week apart (total dose
17 Gy). This regimen was as effective as a regimen considered
to be conventional treatment at the time, namely a multifrac-
tionated regimen of 30 Gy in ten equal fractions (or the
biologically equivalent dose of 27 Gy in six equal fractions)
given daily except at weekends. The main symptoms, namely
cough, haemoptysis, chest pain, and anorexia, were palliated
in high and similar proportions of patients in the two treat-
ment groups, and the main adverse effect of the radio-
therapy, namely dysphagia, was of similar frequency and
severity as recorded daily by the patients themselves using a
diary card. Performance status on admission had a major
prognostic effect, but there was no difference in survival
between the two randomised groups. The two-fraction regi-
men was therefore recommended as it required patients to
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attend only twice for treatment, and greatly reduced the cost
of treatment in terms of machine-time and staff.
The aim of the present study was to investigate whether
only a single fraction of radiotherapy could provide equally
good palliation as the two-fraction regimen used in the
previous study, in the management of patients with inoper-
able NSCLC, a poor performance status, and whose main
symptoms were related to intrathoracic tumour. A survival
difference was not anticipated. In a study of purely palliative
radiotherapy, the intake was restricted to patients with a
poor performance status, because performance status on
admission was known to affect the duration of survival. In
patients with a better status a higher-dose regimen aimed not
only at palliation but also at prolonging survival might be
preferred.
Methods
Eligibility
Patients of either sex and any age were eligible for the trial if
they had previously untreated, inoperable, histologically or
cytologically proved lung carcinoma of any histological type
except small-cell. It was required that their disease was con-
sidered too advanced for 'curative' or long-term palliative
radiotherapy, but that survival was anticipated to exceed 2
months from admission. They had to have poor performance
status, namely WHO grade 2-4 (World Health Organization,
1979), and their main symptoms related to the primary intra-
thoracic tumour, even if metastases were present. Local ethics
committee approval of the protocol and individual patient
consent were required.
The diagnoses were made by the histopathologists from the
referring centres according to the WHO classification (World
Health Organization, 1981). To obtain uniformity of classi-
fication, the slides were later examined by a single reference
histopathologist.
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Pretreatment investigations
The pretreatment investigations included clinical examina-
tion, a postero-anterior chest radiograph, and measurement
of the blood haemoglobin concentration, total white cell and
platelet counts.
Treatment allocation
Clinicians telephoned the MRC Cancer Trials Office and
patients were randomly allocated to one or other of two
treatment regimens using a minimisation procedure, stratify-
ing for histological type and admitting radiotherapist.
Two-fraction regimen: F2 The patients allocated to the F2
regimen were given megavoltage radiotherapy to a total mid-
line dose of 17 Gy, calculated without air correction, in two
fractions of 8.5 Gy 1 week apart.
One-fraction regimen: Fl The patients allocated to the Fl
regimen were given megavoltage radiotherapy in a single
midline dose of 10 Gy, calculated without air correction.
In both F2 and Fl groups, the radiotherapy was delivered
through opposing portals to the primary site and mediastinal
lymph nodes. The field included the loco-regional tumour
volume with a margin of not more than 1 cm, the area,
allowing for leading, not exceeding 200 cm2.
Concurrent steroid administration was recommended for
patients with superior vena cava obstruction, and was also
permitted in other patients.
Reports andinvestigations
A progress report on each patient was completed 1 month
and 2 months after the date of start of radiotherapy, then
once every 2 months up to 1 year, and thereafter once every
6 months. These reports included details of the treatment
given, and details of any metastases.
Assessment ofpalliation by clinicians
The clinician's assessments of the patient's overall condition,
performance status, and degree ofbreathlessness were record-
ed at each attendance according to the categories shown in
Table I. The clinician also asked the patient about the occur-
rence and severity, since the previous attendance, of the
symptoms listed in Table II, and also of nausea, vomiting,
and other symptoms, recording the answers as none, mild,
moderate, or severe.
Daily assessment bypatients
For their first 6 months in the study, the patients completed
an MRC patient diary card (Fayers et al., 1991) every even-
ing after their last meal, recording how they had been feeling
during the previous 24 h using a numerical code (Figure 1).
Statistical methods
Palliation of a symptom was defined as disappearance of the
symptom or improvement by one or more categories (from
Table I General characteristics of the 233 eligible patients on admission
F2 Fl Total
Characteristic No. (%) No. (%) No. (%)
Sex: Male 93 (80) 92 (79) 185 (79)
Age (years):
-45
45-54
55-64
65-74
75+
Histology (assessed locally)
Squamous
Adenocarcinoma
Large-cell
Other
Untyped
Superior vena cava obstruction
Present
Not known
Distant metastases
Present
Not known
Overall condition
0. Excellent
1. Good
2. Fair
3. Poor
4. Very poor
Not known
Performance status (WHO, 1979):
2. up and about > 50% of waking hours, unable
to work, capable of all self-care
3. confined to bed or chair > 50% of waking
hours, limited self-care
4. confined to bed or chair, no self-care
Not known
Degree of breathlessness
0. Climbs hills or stairs without dyspnoea
1. Walks any distance on flat without dyspnoea
2. Walks over 100 yards without dyspnoea
3. Dyspnoea on walking 100 yards or less
4. Dyspnoea on mild exertion, e.g. undressing
Not known
0
3
26
60
27
82
10
13
3
8
5
2
(0)
(3)
(22)
(52)
(23)
(71)
(9)
(11)
(3)
(7)
6
28
56
26
81
11
14
3
8
(1)
(5)
(24)
(48)
(22)
(69)
(9)
(12)
(3)
(7)
(4) 4 (4) 9
3 5
30 (26) 38
0 1
20
55
37
2
l
76
34
5
2
15
23
48
28
0
(1)
(17)
(48)
(32)
(2)
(66)
(30)
(4)
(2)
(13)
(20)
(41)
(24)
12
67
32
5
0
78
32
6
l
4
13
24
43
32
l
(33) 68
(1)
(10)
(57)
(27)
(4)
(67)
(28)
(5)
(3)
(11)
(21)
(37)
(28)
9
54
116
53
163
21
27
6
16
(0)
(4)
(23)
(50)
(23)
(70)
(9)
(12)
(3)
(7)
(4)
(29)
(1)
(14)
(53)
(30)
(3)
2
32
122
69
7
l
154 (67)
66 (29)
11 (5)
2
6
28
47
91
60
1
(3)
(12)
(20)
(39)
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Table II Main symptoms on admission as recorded by the
clinicians
F2 F1 Total
Symptom No. (%) No. (%) No. (%)
Cougha
None 3 (3) 9 (8) 12 (5)
Mild 51 (44) 50 (43) 101 (44)
Moderate 54 (47) 50 (43) 104 (45)
Severe 7 (6) 8 (7) 15 (6)
Haemoptysis
None 61 (53) 63 (54) 124 (53)
Mild 35 (30) 29 (25) 64 (27)
Moderate 19 (16) 24 (21) 43 (18)
Severe 1 (1) 1 (1) 2 (1)
Chest pain
None 50 (43) 46 (39) 96 (41)
Mild 30 (26) 33 (28) 63 (27)
Moderate 30 (26) 31 (26) 61 (26)
Severe 6 (5) 7 (6) 13 (6)
Anorexiaa
None 45 (39) 39 (33) 84 (36)
Mild 32 (28) 42 (36) 74 (32)
Moderate 31 (27) 34 (29) 65 (28)
Severe 7 (6) 2 (2) 9 (4)
Dysphagiaa
None 97 (84) 97 (83) 194 (84)
Mild 11 (10) 11 (9) 22 (9)
Moderate 3 (3) 5 (4) 8 (3)
Severe 4 (3) 4 (3) 8 (3)
a' (F2) not known.
mild to none, from moderate to mild or none, or from severe
to moderate, mild, or none), at one or more assessment.
Duration ofpalliation is expressed (i) as the median duration
of palliation and (ii) as the percentage of patient survival
time during which there was palliation. The variation in these
two statistics is expressed by the interquartile range (Q),
which is the range of the two middle quarters of the results.
Ninety-five per cent confidence intervals (CI) for proportions
are given where appropriate. The Kaplan-Meier estimate was
used to calculate survival curves and a log-rank procedure
was used to calculate confidence intervals for the observed
differences. The effect of factors for prognosis on survival
was assessed by a proportional hazards regression model as
described by Altman (1991). The trial data were managed
using the COMPACT program (COMPACT Steering Com-
mittee, 1991).
Results
Patients in the study
Between February 1988 and September 1989, 235 patients
were randomised from 11 centres in the United Kingdom.
Two patients (1 F2, 1 Fl) were found to have had previously
treated malignant disease and were therefore not eligible for
the trial. There remain 233 (116 F2, 117 Fl) for analysis on
an intention to treat basis. All had NSCLC diagnosed locally,
but in six (3 F2, 3 Fl) the subsequent assessment by the
reference histopathologist was small-cell lung cancer.
N.B. Please fill in date of first entry on this card:
Date!.3:88 D ate ........................................................................................................
WEEK 1
Mon Tue i Wed Thu Fri
CODING
NAUSEA:
1. None
2. Mild
3. Moderate I Sat I Sun I A rm*_
DATE .2- 3 . . . .5
NAUSEA
VOMITING
DIFFICULTY IN
SWALLOWING
ACTIVITY
MOOD
OVERALL
CONDITION
Tick iftreatment
given in hospital
1t. ocvere
VOMITING:
1. None
2. Sick once
3. Sick 2 or 3 times
4. Sick 4 or more times
DIFFICULTY IN SWALLOWING:
1. None
2. Mild soreness only
3. Can swallow solids with difficulty
4. Cannot swallow solids
5. Cannot swallow liquids
ACTIVITY:
1. Normal work/housework
2. Normal work but with effort
3. Reduced activity but
not confined to home
4. Confined to home or hospital
5. Confined to bed
MOOD:
1. Very happy
2. Happy
3. Average
4; Miserable
5. Very miserable
OVERALL CONDITION:
1. Very well
2. Well
3. Fair
4. Poor
5. Very ill
Figure 1 An example of 1 week from a patient diary card. Each card covered 5 weeks.
__ I I I I 1
I I I I I I
=4 5 5 4 4-4
4 4 _ 3 3 _
4 4 3 3 3 3
v I I /v Iv
1 I
Please give details of any other problems or
changes in your general health:-
BIeFATHIMCQ 2cD.
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Of the 233 patients, 79% were male (Table I); 73% were
aged 65 years or over; 70% had a squamous cell tumour; 4%
had superior vena cava obstruction; 29% were reported to
have distant metastases suspected or confirmed; 85% were
assessed by the clinician to be in fair condition or worse
(33% in poor or very poor condition); 33% had performance
status WHO grade 3 or 4, and 65% dyspnoea grade 3 or
worse. The distributions of all these variables were similar in
the two treatment groups.
On admission (Table II), 95% of the patients had cough,
which was moderate or severe in 119 (51%); 47% had hae-
moptysis, 59% chest pain, 64% anorexia, and 16% dys-
phagia.
Radiotherapy received
F2 regimen Of the 116 F2 patients, 108 (93%) received their
radiotherapy according to the protocol. Of the remaining
eight, one died before starting radiotherapy, five died and
one became moribund before the second fraction was due,
and one was given 30 Gy in ten fractions in error.
Fl regimen Of the 117 Fl patients, 114 (97%) received their
radiotherapy according to the protocol. Of the remaining
three, two died before their radiotherapy could be given, and
one was given a single fraction of 8.5 Gy in error.
Additional thoracic radiotherapy Five (4%) of the F2 and 15
(13%) of the Fl patients subsequently required additional
thoracic radiotherapy for recurrent symptomatic disease in
the chest after their allocated trial regimen had been com-
pleted.
Palliation ofmain symptoms as assessed by clinicians
Palliation of the main symptoms (Table III) was achieved in
high proportions of patients, ranging in the F2 group from
48% for cough to 75% for haemoptysis and in the Fl group
from 55% for anorexia to 72% for haemoptysis and chest
pain. Palliation included disappearance of haemoptysis in
64% of the F2 and 54% of the Fl patients, and of the other
main symptoms in 19% to 50%.
The proportions ofpatients in whom palliation was achiev-
ed and in whom symptoms disappeared were similar in the
two treatment groups.
Duration ofpalliation as assessed by clinicians
The duration of palliation as assessed by the clinicians is also
shown in Table III. These measures were necessarily approx-
imate because patients were being assessed at 2 month inter-
vals. The median number of days in palliation ranged in the
F2 group from 46 for anorexia to 73 for haemoptysis, and in
the Fl group from 45 for anorexia to 101 for dysphagia. For
all five of the main symptoms the median duration of pallia-
tion was 50% or more of survival, or of the first year in
patients who survived longer. The findings in the two treat-
ment groups were similar.
Performance status as assessedby clinicians
The clinicians assessed performance status in terms of overall
condition, WHO criteria, and degree of breathlessness (Table
IV). On these criteria, among patients with grade 2 or worse
(defined in Table I) on admission the proportions who im-
proved and the duration of improvement were similar in the
two treatment groups.
Compliance in the use ofpatient diary cards
Patients were asked to complete their patient diary cards
every day during their first 6 months in the trial. Compliance
in providing the data requested was calculated on this basis
but excluding the last 4 weeks of life in patients who died
before 7 months; thus, 36 patients who died within 1 month
of allocation and one centre were not included in this ana-
lysis. Between 76 and 100% of the data requested was receiv-
ed from 64 of the 197 assessable patients, 51-75% from 37,
26-50% from 18, 1-25% from 24, and no data at all from
the remaining 54. Among the four centres with 20 or more
evaluable patients, compliance ranged from 45 to 64% of
requested data. In all, 51% of the patients and 40% of the
centres provided at least half of the data requested.
Similar levels of compliance were observed for each
regimen, between sexes and according to age (details not
shown). In contrast, patients with grade 2 performance status
pretreatment provided 55% of the expected data as opposed
to 44% for patients with grades 3 and 4.
Day-to-day changes recorded bypatients on the patient diary
cards
Among the 68 F2 and 77 Fl patients who returned diary
cards, the percentage reporting a level of physical activity of
grade 3 or 4 on any one day (Figure 2) was similar in the
two treatment groups, the proportion falling during the first
35 days from the start of radiotherapy and levelling out
thereafter. The patterns for overall condition were similar.
Little nausea or vomiting was recorded at any time. In
contrast, there was a marked difference between the groups
in the amount of dysphagia (Figure 3). The percentage of
patients reporting dysphagia of grade 3 or worse each day
rose in the F2 group from levels of around 8% to 40%
during treatment, and fell to the pretreatment level again
during the next 2 weeks, remaining unchanged thereafter.
Little, if any, dysphagia could be attributed to the Fl
regimen. The total numbers of patients recording dysphagia
of grade 3 or worse at any time was 38 (56%) of the F2
group compared with 18 (23%) of the Fl group (difference
33%: 95% CI 17-48%).
Table III Palliation ofmain symptoms as assessed by clinicians
Patients with palliation
Patients in whom Percent ofsurvival
No. ofpatients Patients with symptom Days in in palliation in
with symptom palliation disappeared palliation thefirst year
Symptom Regimen pretreatment No. (%) No. (%) Median Qa Median Qa
Cough F2 112 54 (48) 21 (19) 61 28-108 50 34-76
Fl 108 60 (56) 26 (24) 56 28-101 50 38-73 Haemoptysis F2 55 41 (75) 35 (64) 73 18-142 74 50-89
Fl 54 39 (72) 29 (54) 64 27-103 72 50-83 Chest pain F2 66 39 (59) 26 (39) 51 18-107 50 50-69 Fl 71 51 (72) 31 (44) 56 28-101 50 50-75 Anorexia F2 70 34 (49) 25 (36) 46 22-107 50 45-72
Fl 78 43 (55) 34 (44) 45 15-106 50 50-67 Dysphagia F2 18 11 (61) 7 (39) 46 18-59 50 50-59
Fl 20 13 (65) 10 (50) 101 14-150 62 50-90
aQ = interquartile range.938 MRC LUNG CANCER WORKING PARTY
Table IV Improvement in performance status as assessed by clinicians
Patients with improvement
Percent of
Patients with Days survival time
grade 2 or worse improved improved
Assessment Regimen on admissiona No. (%) Median Qb Median Qb
Overall F2 94 31 (33) 66 32-111 50 46-50
condition Fl 104 43 (41) 52 26-102 50 37-65
Performance F2 115 52 (45) 61 31-110 50 36-63
status (WHO) Fl 116 51 (44) 72 43-115 50 36-66
Degree of F2 99 41 (41) 56 24-108 50 50-74
breathlessness Fl 99 43 (43) 71 27-106 50 37-63
aFor definitions see Table I.
bQ = interquartile range.
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Figure 2 Percentage of patients reporting a level of physical activity of grade 3 or 4 on their diary cards; based on between 33 and
63 F2 --- and between 33 and 67 Fl patients.
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Figure 3 Percentage of patients reporting dysphagia ofgrade 2 or worse on their diary cards; based on between 33 and 62 F2
and between 33 and 66 Fl patients.
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Adverse eventsfollowing treatment
Of the patients reported by the clinicians to have no chest
pain pretreatment, eight (16%) of 49 F2 and eight (20%) of
41 Fl patients were reported to have experienced chest pain
by the time of the first follow-up attendance after radio-
therapy. The corresponding figures for anorexia were 16
(36%) of 45 F2 and 14 (38%) of 37 Fl, for nausea 21 (24%)
of 87 and 15 (17%) of 87, for vomiting 14 (14%) of 99 and
eight (8%) of 95, and for dysphagia 16 (17%) of 93 and 9
(11%) of 84. It is probable that at least some of these events
were caused by the disease rather than the radiotherapy. The
findings in the two treatment groups were similar. At the first
follow-up assessment, dysphagia was reported by the clinic-
ians to have occurred in 25% of all F2 (whether or not they
had dysphagia pretreatment) and 17% of all Fl patients
since the pretreatment assessment. This is in marked contrast
to the daily assessments by the patients themselves (see
above), in which dysphagia was recorded by 56% of the F2
but 23% of the Fl patients.
Two centres mentioned that a few of their patients had
complained of chest pain for 1 day immediately following a
dose of radiotherapy, but this was not formally recorded.
Radiation myelopathy occurred in one patient (F2). Seven-
teen months after her allocated radiotherapy she presented
with altered sensation in her legs, numbness and weakness in
her left leg and bilateral upgoing plantar responses. She had
a sensory level at T8. She died 1 year later. At autopsy there
was no invasion of the spinal cord by tumour. There were
scattered areas of necrosis in the white matter confined to the
irradiated segments (TI to T8), and the blood vessels within
this section showed marked hyaline fibrosis in their walls.
Areas of coagulative necrosis with calcium deposition were
also seen. These findings were considered to confirm a diag-
nosis of radiation myelopathy.
75
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25*
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Survivalfrom allocation
The status of all 233 eligible patients is known for at least 2
years from randomisation. As anticipated, there was no
appreciable difference in survival between the two treatment
groups (Figure 4), the estimated hazard ratio being 1.02,
95% CI 0.81 to 1.29. The median survival was 100 days in
the F2 group and 122 days in the Fl group. At 1 year, 16
(14%) F2 and 11 (9%) Fl patients were alive, and at 2 years,
two (2%) and four (3%), respectively, all but one of whom
have subsequently died.
The treatment comparisons were not affected by adjust-
ment for prognostic factors. Albeit, poor overall condition
and evidence of metastases on admission had major adverse
effects on survival. A separate report on prognostic factors in
this and other MRC NSCLC trials is in preparation.
Discussion
This trial is the second conducted by the Medical Research
Council Lung Cancer Working Party investigating regimens
of palliative radiotherapy in patients with inoperable non-
small-cell lung cancer, too advanced for 'curative' or long-
term palliative radiotherapy. In the first MRC palliative trial
(MRC Lung Cancer Working Party, 1991), a regimen of
17 Gy given in two fractions of 8.5 Gy 1 week apart was
shown to be as effective as a, then, standard regimen of
30 Gy in 10 fractions in palliating chest symptoms.
In the present trial, which differed from the first in that it
was confined to patients with a poor performance status, the
two-fraction regimen was used as the standard and was
compared in a prospective randomised trial with a regimen of
a single fraction of 10 Gy. The aim was to simplify palliative
treatment even further, particularly in the management of
12 la 24
Months from randomisation
Figure 4 Percentage of patients surviving from the date of randomisation: F2 ---, Fl
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patients with a poor performance status and a poor prog-
nosis. The patients were required to have a performance
status of WHO grade 2-4, and their main symptoms related
to the primary intrathoracic tumour, even if metastases were
present. No age limit was set and, in the event, 73% of the
patients were aged 65 years or over.
As recorded by the clinicians, at the time of entry to the
trial, 95% of the 233 patients were complaining of cough,
47% of haemoptysis, 59% of chest pain, 64% of anorexia,
and 16% of dysphagia. On clinicians' assessments at clinic
visits, there was a high and similar level of palliation of all
these symptoms in the two treatment groups. Also, palliation
included disappearance of symptoms in substantial propor-
tions of patients.
The median duration of palliation was similar in the two
treatment groups. It ranged, according to the symptom pal-
liated, from 46 to 73 days in the two-fraction group and
from 45 to 101 days in the single fraction group. For all
these symptoms, the percentage of survival time during which
there was palliation was 50% or more, the results being very
similar in the two groups. The proportions of patients in
whom overall condition, performance status, and degree of
breathlessness improved were also very similar in the two
groups.
It was decided to limit the intake to patients with a poor
performance status because it was felt that in patients with a
good status but inoperable disease, a more aggressive radio-
therapy policy might be preferred. This aspect of manage-
ment is currently being investigated in a trial (MRC Lung
Cancer Working Party, 1989) in which the two-fraction
regimen is being compared with a regimen of 39 Gy in 13
fractions. The results of the whole series of three trials, when
complete, should provide clear guidelines for treating a high
proportion of the patients who present to radiotherapy
departments with inoperable NSCLC (Macbeth & Bolger,
1991). Short fractionation regimens are likely to be activated
more speedily than those of longer duration. This is an
important advantage in a group of patients such as those in
the present trial who have a median survival time of only
about 15 to 20 weeks.
In the present trial, the patients were asked to complete
patient diary cards on nausea, vomiting, difficulty in swallow-
ing, physical activity, mood, and overall condition, ever day
during the first 6 months of the trial. At least half of the data
requested were provided by 51% of the patients and 40% of
the centres. This is a lower level of compliance than in the
first MRC palliative trial. It reflects the difficulty ofobtaining
quality of life data from patients with a poor performance
status. Compliance was unaffected by regimen, sex, or age,
but patients with a better performance status on admission
provided substantially more of the expected data than those
with a poor status. Other groups have also reported difficulty
in collecting quality of life data in patients with poor perfor-
mance status or progressing disease (Ganz et al., 1988; 1989;
Geddes et al., 1990).
As compliance in the use of the diary cards was unaffected
by the regimen, there is no reason to suppose that the
comparison between the regimens is biased. This comparison
showed that although the level of physical activity improved
to a similar extent and over a similar period in the two
groups, the two-fraction regimen was associated with dys-
phagia in 56% of patients compared with 23% in the single-
fraction group. The dysphagia was transient, and had largely
resolved by the time of the next clinic attendance 1 month
after admission. In contrast, at the 1-month assessment, the
clinicians reported that dysphagia had occurred since the
pretreatment assessment in 25% of patients in the two-
fraction group and 17% in the one-fraction group. The diary
card was thus more sensitive in documenting the occurrence
and course of this transient symptom.
In a comparison involving the Karnofsky performance
scale, the Spitzer quality of life evaluation, and linear ana-
logue self-assessment scales, Slevin et al. (1988) also reported
discrepancies between clinicians' and patients' assessments.
We are comparing such assessments in more detail in current
trials in which patients are completing Rotterdam symptom
check lists (de Haes et al., 1986) and hospital anxiety and
depression scales (Zigmond & Snaith, 1983) in addition to
diary cards.
The level and time-scale of the dysphagia in the two-
fraction group were almost identical in the present and first
MRC palliative trials. This confirmatory finding provides
strong evidence for the reliability of the method of recording
it.
Daily diary cards generate large amounts of data. In the
light of experience, we are limiting their use in current trials
to periods when there are likely to be clinically important
changes in symptoms from day to day.
There is concern among some radiotherapists about the
potential immediate adverse effects of large single fractions as
in the single-fraction 10 Gy regimen (Macbeth & Bolger,
1991). The acceptability of this regimen to patients is there-
fore an important finding. Two centres mentioned that a few
of their patients in both treatment groups had complained of
chest pain for 1 day following a dose of radiotherapy. Radia-
tion myelopathy occurred in one patient treated with the
two-fraction regimen. In the first MRC palliative trial it was
suspected in a patient also treated with this regimen. There is
therefore a clear, but small, risk of this late reaction to the
two-fraction regimen. No other adverse effects were con-
sidered to have been specifically caused by the treatment
policies, but in patients with a median survival of little more
than 100 days, palliated symptoms inevitably recurred, and in
some patients, symptoms not present on admission developed
during the course of the trial.
As anticipated at the time the trial was planned, there was
no difference in survival between the two groups. The median
survival was 100 days in the two-fraction group and 122 days
in the single-fraction group.
In conclusion, the present trial and the previous trial
(MRC Lung Cancer Working Party, 1991) have provided
two useful radiotherapy regimens that give high levels of
palliation of the major chest symptoms for at least half ofthe
remaining survival time in high proportions of patients with
inoperable NSCLC. The single-fraction regimen has the
advantage that, unlike the two-fraction regimen, it causes
little if any dysphagia. It involves only a single attendance for
treatment and should prove to be of great value in the
palliative treatment of patients with a poor prognosis.
The following consultants and their colleagues entered 20 or
more patients into the trial: Cambridge: N.M. Bleehen; Glas-
gow: T. Habeshaw, A.N. Harnett, F.R. Macbeth, N.S. Reed,
A.G. Robertson, J.M. Russell, R.P. Symonds, H.M.A. Yosef;
Newcastle: J.M. Bozzino; Sheffield: J.J. Bolger, K.S. Dunn,
I.H. Kunkler, I.H. Manifold, D.J. Radstone, M.J. Whipp.
The remaining patients were entered by the following consul-
tants and their colleagues: Clatterbridge: M.A. Coe, A.J.
Slater; Leicester: F.J.F. Madden; Middlesex: M.F. Spittle;
Mount Vernon: S. Dische, D.C. Fermont, M.I. Saunders;
Nottingham: D.A.L. Morgan; Oxford: C.J. Alcock, K.R.
Durrant, A.H. Laing; Royal Marsden: J.R. Yarnold.
The reference histopathologist was P.S. Hasleton.
Local coordinators were: Denise Bircumsaw, Dorothy Cor-
rigan, Linda Cram, Elizabeth Crossley, Mandy Dixon, Lesley
Grant, Cathy Hutchinson, Viveca Marmur, Karen McGregor,
Susan Mitchell, Alison Pickett, Jane Regan, Clara Schuer-
man, Teresa Young.
The trials office data managers were: Elizabeth Brodnicki,
Julie Cartmell, Grazyna Lallemand and Sheila Thornton.PALLIATIVE RADIOTHERAPY FOR NSCLC 941
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